FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754311586> ?p ?o ?g. }

• W2754311586 endingPage "124" @default.
• W2754311586 startingPage "113" @default.
• W2754311586 abstract "This study evaluated the independent contribution of voriconazole to the development of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for important confounding factors, particularly immunosuppression. This international, multicenter, retrospective, cohort study included adult patients who underwent lung transplantation during 2005-2008. Cox regression analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependent variables, on the risk of developing biopsy-confirmed SCC. Nine hundred lung transplant recipients were included. Median follow-up time from transplantation to end of follow-up was 3.51 years. In a Cox regression model, exposure to voriconazole alone (adjusted hazard ratio 2.39, 95% confidence interval 1.31-4.37) and exposure to voriconazole and other azole(s) (adjusted hazard ratio 3.45, 95% confidence interval 1.07-11.06) were associated with SCC compared with those unexposed after controlling for important confounders including immunosuppressants. Exposure to voriconazole was associated with increased risk of SCC of the skin in lung transplant recipients. Residual confounding could not be ruled out because of the use of proxy variables to control for some confounders. Benefits of voriconazole use when prescribed to lung transplant recipients should be carefully weighed versus the potential risk of SCC. EU PAS registration number: EUPAS5269. This study evaluated the independent contribution of voriconazole to the development of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for important confounding factors, particularly immunosuppression. This international, multicenter, retrospective, cohort study included adult patients who underwent lung transplantation during 2005-2008. Cox regression analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependent variables, on the risk of developing biopsy-confirmed SCC. Nine hundred lung transplant recipients were included. Median follow-up time from transplantation to end of follow-up was 3.51 years. In a Cox regression model, exposure to voriconazole alone (adjusted hazard ratio 2.39, 95% confidence interval 1.31-4.37) and exposure to voriconazole and other azole(s) (adjusted hazard ratio 3.45, 95% confidence interval 1.07-11.06) were associated with SCC compared with those unexposed after controlling for important confounders including immunosuppressants. Exposure to voriconazole was associated with increased risk of SCC of the skin in lung transplant recipients. Residual confounding could not be ruled out because of the use of proxy variables to control for some confounders. Benefits of voriconazole use when prescribed to lung transplant recipients should be carefully weighed versus the potential risk of SCC. EU PAS registration number: EUPAS5269." @default.
• W2754311586 created "2017-09-25" @default.
• W2754311586 creator A5004901727 @default.
• W2754311586 creator A5017851529 @default.
• W2754311586 creator A5032149249 @default.
• W2754311586 creator A5038536408 @default.
• W2754311586 creator A5043487227 @default.
• W2754311586 creator A5044879111 @default.
• W2754311586 creator A5056354342 @default.
• W2754311586 creator A5057690903 @default.
• W2754311586 creator A5059942127 @default.
• W2754311586 creator A5061092373 @default.
• W2754311586 creator A5063474662 @default.
• W2754311586 creator A5066236820 @default.
• W2754311586 creator A5067667857 @default.
• W2754311586 creator A5074307674 @default.
• W2754311586 creator A5082709093 @default.
• W2754311586 creator A5083199308 @default.
• W2754311586 creator A5083214889 @default.
• W2754311586 creator A5084447763 @default.
• W2754311586 creator A5088874444 @default.
• W2754311586 creator A5090905966 @default.
• W2754311586 date "2018-01-01" @default.
• W2754311586 modified "2023-09-26" @default.
• W2754311586 title "Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study" @default.
• W2754311586 cites W101095248 @default.
• W2754311586 cites W1570251120 @default.
• W2754311586 cites W1954100997 @default.
• W2754311586 cites W1968024835 @default.
• W2754311586 cites W197690493 @default.
• W2754311586 cites W1990223919 @default.
• W2754311586 cites W1995168173 @default.
• W2754311586 cites W1998504740 @default.
• W2754311586 cites W2014116071 @default.
• W2754311586 cites W2018889597 @default.
• W2754311586 cites W2025025945 @default.
• W2754311586 cites W2038340344 @default.
• W2754311586 cites W2046244162 @default.
• W2754311586 cites W2059030563 @default.
• W2754311586 cites W2069914325 @default.
• W2754311586 cites W2071257253 @default.
• W2754311586 cites W2082695689 @default.
• W2754311586 cites W2090225402 @default.
• W2754311586 cites W2101785863 @default.
• W2754311586 cites W2106444474 @default.
• W2754311586 cites W2108443705 @default.
• W2754311586 cites W2117053752 @default.
• W2754311586 cites W2119003182 @default.
• W2754311586 cites W2123134253 @default.
• W2754311586 cites W2133408276 @default.
• W2754311586 cites W2135256580 @default.
• W2754311586 cites W2154872776 @default.
• W2754311586 cites W2160097634 @default.
• W2754311586 cites W2163554629 @default.
• W2754311586 cites W2168918047 @default.
• W2754311586 cites W2170102686 @default.
• W2754311586 cites W2798594359 @default.
• W2754311586 cites W3183939991 @default.
• W2754311586 doi "https://doi.org/10.1111/ajt.14500" @default.
• W2754311586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28898527" @default.
• W2754311586 hasPublicationYear "2018" @default.
• W2754311586 type Work @default.
• W2754311586 sameAs 2754311586 @default.
• W2754311586 citedByCount "26" @default.
• W2754311586 countsByYear W27543115862018 @default.
• W2754311586 countsByYear W27543115862019 @default.
• W2754311586 countsByYear W27543115862020 @default.
• W2754311586 countsByYear W27543115862021 @default.
• W2754311586 countsByYear W27543115862022 @default.
• W2754311586 countsByYear W27543115862023 @default.
• W2754311586 crossrefType "journal-article" @default.
• W2754311586 hasAuthorship W2754311586A5004901727 @default.
• W2754311586 hasAuthorship W2754311586A5017851529 @default.
• W2754311586 hasAuthorship W2754311586A5032149249 @default.
• W2754311586 hasAuthorship W2754311586A5038536408 @default.
• W2754311586 hasAuthorship W2754311586A5043487227 @default.
• W2754311586 hasAuthorship W2754311586A5044879111 @default.
• W2754311586 hasAuthorship W2754311586A5056354342 @default.
• W2754311586 hasAuthorship W2754311586A5057690903 @default.
• W2754311586 hasAuthorship W2754311586A5059942127 @default.
• W2754311586 hasAuthorship W2754311586A5061092373 @default.
• W2754311586 hasAuthorship W2754311586A5063474662 @default.
• W2754311586 hasAuthorship W2754311586A5066236820 @default.
• W2754311586 hasAuthorship W2754311586A5067667857 @default.
• W2754311586 hasAuthorship W2754311586A5074307674 @default.
• W2754311586 hasAuthorship W2754311586A5082709093 @default.
• W2754311586 hasAuthorship W2754311586A5083199308 @default.
• W2754311586 hasAuthorship W2754311586A5083214889 @default.
• W2754311586 hasAuthorship W2754311586A5084447763 @default.
• W2754311586 hasAuthorship W2754311586A5088874444 @default.
• W2754311586 hasAuthorship W2754311586A5090905966 @default.
• W2754311586 hasBestOaLocation W27543115861 @default.
• W2754311586 hasConcept C126322002 @default.
• W2754311586 hasConcept C141071460 @default.
• W2754311586 hasConcept C16005928 @default.
• W2754311586 hasConcept C167135981 @default.
• W2754311586 hasConcept C201903717 @default.
• W2754311586 hasConcept C207103383 @default.

• next